US › Healthcare

Tempest Therapeutics Inc (TPST)

US · Healthcare · Biotechnology

$0.90-26.03%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.2M

EPS

$-0.34

EPS estimate

$-0.30

EPS came in at -0.34 against a street estimate of -0.30 — a miss of 13.3%.

Key statistics

Market cap

$13.4M

Forward P/E

0.0

P/B

22.94

Book value

$0.06

EPS (TTM)

$-3.68

52-week high

$12.23

52-week low

$0.76

50-day MA

$1.00

200-day MA

$1.91

Beta

-1.66

Analyst view

Analysts rate Tempest Therapeutics Inc a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $11.00.

Shareholding

Insiders

31.78%

Institutions

29.57%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.41%
Geode Capital Management, LLC	0.53%
Vanguard Fiduciary Trust Co	0.42%
BlackRock Inc	0.24%
FMR Inc	0.20%
Citadel Advisors Llc	0.12%
Sabby Management LLC	0.11%
Northern Trust Corp	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tempest Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.